SLXN Latest Press Releases

-- March 17, 2026 --

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Globe Newswire 5:11 PM

-- March 5, 2026 --

Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting Globe Newswire 8:00 AM

-- January 21, 2026 --

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit Globe Newswire 8:30 AM

-- January 6, 2026 --

Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025's Significant Achievements and Outlining Upcoming Milestones for 2026 Globe Newswire 7:30 AM

-- December 16, 2025 --

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer Globe Newswire 8:40 AM

-- December 2, 2025 --

Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer Globe Newswire 8:00 AM

-- November 26, 2025 --

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference Globe Newswire 7:30 AM

-- November 25, 2025 --

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer Globe Newswire 9:15 AM

-- November 12, 2025 --

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Globe Newswire 9:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software